From BigGo Finance · BigGo Finance · · 1m 10s
Peptron Gets Phase 1 Approval for Monthly Obesity Drug
Peptron secures South Korea's Phase 1 approval for once-monthly obesity drug PT403, targeting first dose in December.
In brief
Peptron secures South Korea's Phase 1 approval for once-monthly obesity drug PT403, targeting first dose in December. Peptron received South Korea's Ministry of Food and Drug Safety approval for PT403, a once-monthly obesity treatment candidate, with first dose planned for December. Originally reported by BigGo…
Peptron Wins Phase 1 Approval

Peptron received approval from South Korea's Ministry of Food and Drug Safety for PT403, a once-monthly obesity treatment candidate.
PT403 Uses SmartDepot Platform
PT403 applies Peptron's proprietary SmartDepot platform to semaglutide to extend dosing from weekly to monthly.
First Dose Targeted for December
The company plans to administer the first dose in December after completing follow-up procedures.
Trial at Chungnam National University Hospital

The Phase 1 trial will evaluate safety, tolerability and pharmacokinetics in 22 healthy adults.
Preclinical Results at ADA Meeting
Peptron presented preclinical results for PT403 at the American Diabetes Association meeting in June.
The key point
Peptron received South Korea's Ministry of Food and Drug Safety approval for PT403, a once-monthly obesity treatment candidate, with first dose planned for December.
Read the TL;DR — this story on one card.





